Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.19 Insider Own5.24% Shs Outstand49.05M Perf Week-3.78%
Market Cap87.31M Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float46.48M Perf Month-5.32%
Income-9.51M PEG- EPS next Q-0.08 Inst Own19.22% Short Float / Ratio0.51% / 2.45 Perf Quarter-25.21%
Sales1.00M P/S87.31 EPS this Y27.59% Inst Trans-0.91% Short Interest0.24M Perf Half Y-18.72%
Book/sh1.32 P/B1.35 EPS next Y-52.38% ROA-12.99% Target Price16.50 Perf Year-32.58%
Cash/sh1.05 P/C1.69 EPS next 5Y20.00% ROE-13.81% 52W Range1.71 - 2.73 Perf YTD-13.17%
Dividend- P/FCF- EPS past 5Y2.16% ROI-14.61% 52W High-34.80% Beta0.86
Dividend %- Quick Ratio18.92 Sales past 5Y-20.00% Gross Margin83.86% 52W Low4.09% ATR0.10
Employees13 Current Ratio18.92 Sales Q/Q- Oper. Margin-1064.14% RSI (14)43.47 Volatility3.97% 5.00%
OptionableYes Debt/Eq0.01 EPS Q/Q80.27% Profit Margin-951.39% Rel Volume0.21 Prev Close1.81
ShortableYes LT Debt/Eq0.01 EarningsNov 09 AMC Payout- Avg Volume97.04K Price1.78
Recom1.00 SMA20-2.98% SMA50-8.06% SMA200-18.23% Volume20,634 Change-1.66%
Date Action Analyst Rating Change Price Target Change
Mar-10-21Initiated Maxim Group Buy $15
Mar-25-19Resumed B. Riley FBR Buy $22
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
Nov-19-23 06:00PM
Nov-10-23 09:57AM
Oct-27-23 01:00AM
Oct-10-23 07:00PM
Oct-04-23 07:00PM
09:11AM Loading…
Sep-29-23 09:11AM
Sep-27-23 07:00PM
Aug-21-23 08:00AM
Aug-17-23 07:00PM
Aug-16-23 07:00PM
Aug-15-23 07:00PM
Aug-14-23 07:00PM
Aug-10-23 02:12PM
Jul-23-23 09:56AM
Jun-29-23 06:00AM
05:00AM Loading…
May-30-23 05:00AM
May-14-23 07:00PM
May-12-23 07:47PM
Apr-30-23 07:00PM
Mar-22-23 11:19AM
Mar-09-23 06:00PM
Feb-27-23 04:57AM
Feb-20-23 06:00PM
Feb-08-23 06:00PM
Jan-30-23 06:00PM
Jan-12-23 06:00PM
Jan-10-23 10:00PM
Jan-09-23 10:00PM
Jan-05-23 06:00PM
Dec-06-22 06:00PM
06:00PM Loading…
Dec-05-22 06:00PM
Nov-29-22 05:43PM
Nov-18-22 05:40AM
Oct-13-22 10:50AM
Sep-15-22 07:00PM
Sep-14-22 07:00PM
Sep-13-22 07:00PM
Aug-19-22 06:23AM
Aug-16-22 06:30AM
Aug-09-22 07:00PM
Jul-27-22 06:30AM
Jul-26-22 06:30AM
Jul-21-22 07:00PM
Jun-29-22 07:00PM
Jun-22-22 07:00PM
Jun-13-22 06:35AM
Jun-08-22 09:05AM
May-25-22 06:10AM
May-06-22 09:48AM
Apr-21-22 07:00PM
Apr-20-22 07:00PM
Apr-12-22 11:00PM
Apr-11-22 06:30AM
Apr-08-22 09:38AM
Apr-07-22 07:00PM
Apr-06-22 11:15AM
Mar-17-22 06:30AM
Mar-15-22 06:30AM
Mar-01-22 05:20AM
Feb-28-22 06:30AM
Feb-22-22 06:30AM
Feb-14-22 01:12PM
Feb-01-22 06:30AM
Jan-31-22 06:30AM
Jan-27-22 06:30AM
Jan-26-22 06:30AM
Dec-13-21 06:30AM
Dec-10-21 06:30AM
Nov-23-21 05:04AM
Nov-22-21 06:30AM
Nov-15-21 12:40PM
Nov-11-21 06:00PM
Nov-10-21 06:00PM
Nov-03-21 07:30PM
Oct-21-21 06:30AM
Sep-02-21 11:00PM
Sep-01-21 06:30AM
Aug-30-21 06:30AM
Aug-16-21 11:23AM
Aug-12-21 07:00PM
Jul-06-21 06:30AM
Jun-29-21 06:30AM
Jun-28-21 08:37AM
Jun-26-21 07:34AM
Jun-22-21 06:07AM
Jun-21-21 06:30AM
Jun-18-21 03:23PM
Jun-14-21 06:30AM
Jun-07-21 06:30AM
May-28-21 06:25AM
May-17-21 09:04AM
May-13-21 04:30PM
May-05-21 08:00PM
Apr-26-21 05:45AM
Apr-22-21 06:30AM
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.